Trauma to skeletal muscle and strenuous work or exercise performed by muscle can lead to an immediate injury and loss of strength. We and others have hypothesized that the initial injury can initiate a cascade of events leading to additional injury in the ensuing hours and days. 1, 19 This cascade includes an inflammatory phase, beginning 2 to 6 hours after the initiating event. 1 In this phase, neutrophils and macrophages invade the damaged tissue and are primarily responsible for removal of that tissue over the next several days. We and others have also proposed that the inflammatory response may result in a secondary injury because of spillover of the inflammatory response from damaged tissue onto tissue that was not initially damaged (ie, bystander injury). 1, 19 Consensus is lacking on how the recovery from skeletal muscle injury can be optimized. 21 One approach has been to reduce or restrict the inflammatory response so that bystander injury is reduced. Support for this premise has come from animal studies in which recovery from contraction-or strain-induced muscle injury is enhanced when neutrophil migration and/or oxidant production is reduced by gene deletion or administration of neutralizing antibodies. 9, 52 However, evidence is available arguing that impairment of the inflammatory response can have adverse effects. For example, we have demonstrated in 3 animal studies that elimination of the cytokine, tumor necrosis factor a, or the chemokine, monocyte chemoattractant protein-1 (CCL2), and/or their receptors can impair the functional recovery of injured muscle. 70, 71, 73 Without a doubt, the most common means for dampening the inflammatory response in humans after musculoskeletal injuries is ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs). It is estimated that more than one-fifth of all Americans use NSAIDs regularly. 13 NSAIDs exhibit anti-inflammatory effects via inhibition of prostaglandin and reactive oxygen species production as well as suppression of phagocyte migration, aggregation, and other functions. 76 Despite these actions of NSAIDs, which might be beneficial in the recovery from muscle injury, NSAIDs are also known to suppress satellite cell or myoblast number after injury, 5, 40, 43 which presumably would have a detrimental effect on recovery, particularly in the later stages. Most narrative reviews of the overall efficacy of NSAIDs on recovery from muscle injuries have been inconclusive. 3, 14, 42, 60, 76 Because of this and because NSAIDs can have adverse effects on the gastrointestinal tract, kidneys, and liver, even resulting in death in extreme cases, 13 we believed that a rigorous, quantitative analysis of the literature was warranted. It would seem that a substantial beneficial effect of NSAIDs on muscle injury recovery would have to be found to offset the possible adverse effects that might occur with sustained ingestion of NSAIDs. Thus, our objective was to conduct an extensive systematic review combined with a meta-analysis to clarify the effect of NSAIDs on the recovery from acute muscle injury. We are unaware of any previous attempt to address the issue using this method.
METHODS

Systematic Review
A thorough search of the research literature was performed conforming to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement. 45 The research question upon which the search was based was ''Compared with the control condition, do NSAIDs affect the recovery from acute skeletal muscle injury?'' Muscle injury was defined by the presence of strength loss, soreness, and/or increase in blood creatine kinase (CK) level. These markers of injury were chosen because of their common use and, in the case of strength, because of its ability to provide the best assessment of muscle functional capacity. We have previously discussed in detail the advantages and disadvantages of these and other indices of muscle injury. 72 For assessment in human studies, muscle soreness was operationally defined as a rating of pain or soreness experienced in terms of a standardized pain scale (eg, 100-mm visual analog scale). Strength loss was operationally defined as (1) the reduction in peak force or torque produced during an isometric or isokinetic contraction as either a maximal voluntary or an electrically stimulated contraction or (2) the decrease in the maximum load that could be lifted during a single isotonic contraction. Although our literature search began September 2009 and continued through January 2016, we did not impose any restriction on the time frame in which a study was conducted. Study Inclusion and Exclusion Criteria. Studies meeting the following criteria were considered for review: (1) the study was conducted on animals or humans who experienced an acute injury to skeletal muscle, (2) some form of strength loss, muscle soreness, and/or blood CK level was measured, and (3) the study contained at least 2 trials (or separate groups of subjects) in which the subjects were administered NSAIDs in 1 trial (or group) and a control condition in the other. The control condition usually equated to administration of a placebo but that stringent of a restriction could not be met in half of the studies using animals. 44, 47, 54 Studies were excluded for the following reasons: (1) a means of NSAID administration was used in which there was uncertainty about the NSAID dose being delivered (eg, when using topical creams), (2) the effect observed in a study could not be attributed specifically to NSAID administration, (3) the study included subjects with a chronic muscle disease or an animal model of it (eg, mdx mice, which model Duchenne muscular dystrophy), and (4) insufficient data were reported in the study to calculate an effect size. Before excluding studies for insufficient data, we attempted to retrieve the necessary data by contacting the corresponding author.
Selection of Studies. A total of 5343 study reports were originally identified through the database searches and review of article reference lists. Of those, 5207 were excluded based on review of titles and abstracts. At this point, 136 study reports were evaluated via a careful review of the full text. On the basis of the inclusion and exclusion criteria described above, 94 study reports were excluded, leaving a total of 42. Two study reports provided duplicate data from the same study and, thus, only data from 41 studies were included in the meta-analyses. Each phase of the study selection process was performed independently by 2 of the present study's authors. Any disagreements were settled through mediation from a third author. Author roles varied by study. The review and selection processes for the studies in the systematic review are summarized in Appendix Figure  A1 , available in the online version of this article.
Data Extraction and Assessment of Study Risk of Bias.
For the meta-analyses, strength loss, soreness, and blood CK level data were extracted in the form of means, standard deviations (SDs), and sample sizes for both the NSAID and control conditions in all studies except in the study by Rother et al, 56 which used the mean difference between NSAID and control groups, SD of difference between NSAID and control groups, and sample sizes. These descriptors were reported after injury either for posttreatment measurements only or for changes from pre-to posttreatment. For each study, data were extracted only for all postinjury time points after the first administration of NSAID or the control condition. Data extraction was conducted independently by 2 of the present study's authors. Any disagreements were settled through mediation from a third author. Author roles varied by study. A risk of bias assessment was performed on all studies as recommended by the Cochrane Collaboration. 26 In these assessments, we evaluated 6 categories: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting bias.
Meta-analysis
The extracted strength loss, soreness, and blood CK level data were converted to a standard format by calculating the standardized mean difference, which will be referred to as the effect size (ES). The ES calculation was set up so that a positive ES indicated NSAID efficacy. For independent group studies in which means, SDs, and sample sizes were reported (ie, the most common scenario [n = 30 studies]), standardized mean differences were calculated as detailed by Borenstein et al. 7 For the 11 crossover studies in which means, SDs, and sample sizes were reported, standardized mean difference was calculated as we have described previously. 69, 75 Because these calculations require intertrial correlations and no individual subject data were available to use for such calculations, with the exception of 1 study, 43 we assumed an intertrial correlation of 0.8 for strength measures and 0.5 for soreness and CK measures. The 0.8 intertrial correlation was that used in a previous meta-analysis work investigating strength changes. 75 We tested the effect of these assumptions on our calculation of the overall ES using a sensitivity analysis. In the calculation of the overall ES, when a study measured strength loss, soreness, and/or blood CK level under multiple conditions (eg, used more than 1 type of contraction to assess strength) or at multiple time points, standardized mean differences and variances were averaged across the different condition levels or time points.
Meta-analyses were run using a random-effects model. A random-effects model was chosen over a fixed-effect model because of the wide variation in experimental factors among the 41 studies (eg, NSAID type and dosage, muscle group injured, outcomes assessed). The extent of heterogeneity (ie, between-study variation in ES) was assessed using both the I 2 value and a chi-square test of the Q value. 7 Because moderate heterogeneity was observed, we sought to determine the role of various experimental factors in explaining that heterogeneity; experimental factors can be treated as moderator variables in a meta-analysis. Metaregression, using a method-of-moments model, was used to assess continuous moderator variables (eg, duration of NSAID use, time after injury for outcome measurement). Subgroup meta-analysis was used to assess nominal moderator variables in which subsets of studies are compared using Q tests on the basis of analysis of variance (ANOVA). This test, along with the assumption of a common among-study variance component across subgroups, was used to probe several factors: for example, study research design (crossover vs randomized controlled trial [RCT]), subject type (human vs animal), type of NSAID, and type of outcome measure (strength loss vs soreness vs blood CK level). Only subgroups with 5 or more studies were analyzed. In studies that evaluated more than 1 level of the experimental factor (eg, a study measuring both strength loss and soreness during the subgroup metaanalysis evaluating the effect of outcome measure type), an ES was calculated for each level and each ES was treated as if it originated from an independent study.
Meta-analyses and meta-regressions were conducted by use of the software Comprehensive Meta-Analysis (version 3.3; Biostat Inc). An a level of .05 was used in all analyses except when a moderator variable with more than 2 levels was being probed in a subgroup meta-analysis; in this situation, a Benjamini-Hochberg false-discovery rate adjustment was applied to the a level to correct for multiple post hoc comparisons. Effect sizes of 0.2, 0.5, and 0.8 were considered to be small, moderate, and large, respectively. 11 Publication bias in the primary meta-analysis was assessed using a funnel plot of study ES versus standard error.
RESULTS
Description of Included Studies
In total, 41 studies between 1985 and 2015 were included for meta-analysis of the effect of NSAIDs on recovery from acute muscle injury as assessed by strength loss, soreness, and/or blood CK level. The characteristics of these investigations are summarized in the online Appendix Table A1 . Thirty-seven studies were published in peerreviewed journals. One study was published as a conference proceeding in a journal supplement. 15 Two studies were published as master's theses 39, 67 and 1 study as a doctoral dissertation. 23 Twenty-nine studies used an RCT research design with 2 or more independent groups while 11 used a crossover experimental research design, and 1 study was a synthesis of 3 mini-studies using 2 or more independent groups. Eleven studies reported receiving funding from a NSAID manufacturer to test its product(s).
z The most common means for inducing injury was the performance of a bout of high-force eccentric contractions (n = 31 studies). In the remaining 10 studies, 5 used downhill running or stepping, 16 33 and 4 used a traumatic strain or crush injury, with 3 of the 4 being animal studies. 47, 54, 55, 68 The NSAIDs used in the 41 studies included aspirin, celecoxib, diclofenac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, meloxicam, naproxen, oxaprozin, and piroxicam; of these, only celecoxib is a COX-2 selective NSAID, and it was used in only 1 study. 49 In the 34 studies using human subjects, there were 979 subjects total; 666 and 167 were males and females, respectively, while the sex for 146 was not specified. Most (n = 27) of the human studies reported a subject age range of 18 to 45 years, whereas Baldwin et al 2 reported a mean age of 60. Eight different muscle groups were injured and tested in the human studies; the knee extensors and elbow flexors were the most common. Of the 7 studies using animals, 1 study used male mice, 2 studies used rabbits (with 1 study using males and the other study unknown sex), and 4 used rats (3 studies using females and 1 study using males). Data from a total of 439 animals were used in the analysis. All animal studies studied the ankle dorsiflexor muscles.
Cochrane risk of bias assessment was performed on all 41 studies. Overall, risk of bias appeared to be minor. Seven studies were judged to have a high bias for selective reporting, 17, 30, 32, 46, 65, 66, 68 and 1 study was judged to have a high bias for blinding of participants and personnel and blinding of outcome assessment. 53 A high percentage of studies (ie, 66%-100%) had unclear bias determinations for allocation concealment and for incomplete outcome data evaluations. This is believed to be due to a limitation in study reporting and not a limitation in how the studies were conducted.
Meta-analysis
In total, 547 ESs were calculated for the 41 studies, yielding an average of~13 ESs per study. From these ESs, a single average ES was then calculated for each study and used in the remaining analyses except where noted. Considerable variation was found in ESs among the 41 studies, with study ESs ranging from 20.80 to 2.53 ( Figure 1 ). Only the first 8 studies in Figure 1 exhibited negative ESs, meaning that the control condition did better overall than the NSAID condition in those studies. Conversely, 33 of the 41 studies exhibited positive, beneficial effects of NSAID use compared with control. Meta-analysis on the 41 studies yielded a statistically significant and small to moderate overall ES, indicating that NSAID use does typically reduce the markers of acute muscle injury (overall ES = 0.34; 95% confidence interval [CI], 0.17-0.52; P = .0001) (Figure 1 ). The ES calculated for each subgroup of studies using the different injury markers (ie, strength loss vs soreness vs blood creatine level) is shown in Figure 2 ; these ESs were similar in magnitude (ie, 0.29-0.47) and all were significantly greater than zero, thus indicating a beneficial effect of NSAIDs regardless of the type of injury marker used. The study by O'Grady et al 46 had by far the most beneficial influence on the overall ES. If that study was removed from the meta-analysis, the overall ES would fall to 0.26 but it would still be highly significant (P = .0003) and still indicate a small beneficial effect of NSAID use. Three studies had a markedly larger ES (bottom 3 studies in Figure 1) . 41, 46, 54 If those were removed from the meta-analysis, the overall ES would fall to 0.19 and it would remain a highly significant (P = .0006), small effect. In our assessment of publication bias, a funnel plot was examined for asymmetry (Appendix Figure A2) . Asymmetry was noticeable but was not that typically associated with publication bias. The atypical asymmetry seemed to result mostly from the Meamarbashi and Rajabi 41 and O'Grady et al 46 studies. Because of this observation and the substantial heterogeneity observed (discussed below), it was not feasible to calculate an overall ES adjusted for publication bias using the Duval and Tweedie's trim and fill correction. 50, 63 Between-study variance in ES was determined to be moderate (ie, I 2 = 57%) and was statistically significant (Q-df = 52.4, P = .000005). This justifies investigating potential moderator variables to explain the between-study variance using subgroup meta-analysis and meta-regression. Table 1 summarizes the findings of the subgroup meta-analyses probing possible roles for 11 nominal variables in explaining ES Figure 1 . Forest plot of effect sizes (ESs) from the 41 studies that assessed the effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on the markers of muscle injury. For each study, the number in parentheses after the publication year is the reference number. A square in the plot represents the ES for a given study with the size of the square being proportional to the weighting of that study in the meta-analysis. A horizontal line indicates the 95% confidence interval (CI) for a study ES. Studies are arranged from the lowest to highest ES. The diamond at the bottom represents the overall ES calculated using a random-effects model. The width of the diamond represents the 95% CI for the overall ES. variation among the 41 studies. No significant difference was found between the ES for studies funded by a NSAID manufacturer and the ES for those that were not (P = .70). No significant difference was noted in ES between studies using different injury markers or subject sexes or between studies using animals and those using humans (P 0.29). Study ES was also unaffected by the particular NSAID used or when the NSAID treatment began (ie, before or after injury) (P .19). Only 2 factors were statistically significant. One was muscle group location, specifically upper versus lower body muscle groups, in studies using humans (P = .045); the ES for studies using lower body muscle groups was~5-fold greater than that for studies using upper body muscle groups. However, comparison of human studies using knee extensors against those using elbow flexors did not reach statistical significance (P = .25). The ES for studies with a Cochrane risk of bias assessment identified as high in at least 1 category was markedly greater than the ES for the studies with no high risk of bias (0.76 vs 0.24, P = .02). Of the 26 subgroups created to examine the 11 experimental factors, none had a negative ES, which should occur if NSAIDs had an adverse effect on injured muscle. Table 2 summarizes the findings of meta-regression analyses probing possible roles for 5 continuous moderator variables in explaining ES variation among the 41 studies. When all studies were analyzed together, neither the duration of NSAID administration nor the time after injury for an outcome measurement was a significant factor (P .07). However, an inverse relationship was found between study ES and duration of NSAID administration when only animal studies were analyzed (P = .02) (Table 2, Figure 3A) but the relationship was a positive one in the human studies (P = .002) (Table 2, Figure 3B ). However, the significant positive relationship was lost in the human studies if the O'Grady et al 46 study was removed from the analysis. The relationship between study ES and time of outcome measurement in the animal studies was also an inverse one (P = .01), meaning that studies measuring outcomes at relatively long times after injury induction tended to have lower ES and after~3.5 weeks after injury negative ones (Table 2, Figure 4A ). On the contrary, no relationship was found between study ES and time of outcome measurement in the human studies (Table 2, Figure 4B ), although the latest outcome measurement was conducted at 2 weeks after injury in human studies, compared with 6 weeks after injury in the animal studies.
DISCUSSION
The main finding of this study was that NSAID use on average reduces strength loss, soreness, and blood CK levels after an acute muscle injury. A comparison between subgroups of human studies indicates that NSAIDs may be more effective in treating lower body muscle injuries compared with upper body injuries. Although no overall difference was found between studies using humans and those using animals, both outcome measurement time after injury and NSAID administration duration were inversely related to study ES for animal studies but not for human studies. This suggests there may be a species difference in the effect of NSAIDs on the recovery from muscle injury. Alternatively, experimental Sample size (n) refers to the number of independent groups of subjects in a subgroup. Values within square brackets represent the 95% confidence interval for the ES. Analyses were run on data for human and animal studies combined unless otherwise noted. All drug doses were converted to an ibuprofen-equivalent dose using data from Chou and colleagues. 10 differences between human and animal studies may explain the apparent species difference. This will be discussed later. Potential limitations of our systematic review and metaanalysis include (1) inclusion of unpublished studies or ones with a high risk of bias, (2) publication bias, and (3) failure to know the intertrial correlations in most of the 11 crossover studies. Inclusion of unpublished data can sometimes alter meta-analysis findings such that they lose their statistical significance, indicating that the published literature is affected by selective reporting biases. 34 For this reason, it is recommended that the results of studies found in the gray literature should be included in metaanalyses. 27 Thus, we included in our meta-analyses the 4 unpublished studies found in our systematic review. If we removed these studies from our meta-analysis, the overall ES is virtually unchanged (ie, rises from 0.34 to 0.36) and remains statistically significant (P = .0002).
Eight studies in our analysis were identified as having a high risk of bias for 1 or more of the 6 categories in the Cochrane risk of bias assessment tool. Seven of the 8 studies had a high risk of bias for selective reporting, meaning that they did not report all of the study's prespecified outcomes. We are unable to determine the effect the omitted data might have on the overall ES. However, if the 8 studies were excluded from our analysis, the overall ES would decrease from 0.34 to 0.22 but would still be statistically significant (P = .004).
Publication bias occurs when research that appears in the published literature is systematically unrepresentative of the population of completed studies. 61 The tendency is for studies with nonsignificant and/or negative findings to not be published. 24, 28 Meta-analyses will therefore tend to be biased toward the published studies because of the difficulty of identifying unpublished research and obtaining from those studies the results necessary to calculate the ES. In our assessment of the effect of publication bias on the primary meta-analysis, asymmetry was noted in the funnel plot (Appendix Figure A2) , but it could not be totally attributed to publication bias. As a result, we were not able to adequately estimate the effect of publication bias on our overall ES.
The remaining limitation to discuss is not knowing the intertrial correlations in most of the studies with a crossover research design. 7 We were able to calculate an intertrial correlation only for the strength measures in the Mikkelsen et al 43 study. The 10 other crossover studies failed to report this correlation or to provide the data necessary to calculate the correlation. This is a common issue for data extraction from primary research studies. 7 Because of this, Borenstein and colleagues 7 have recommended that a sensitivity analysis be conducted by assessing the effect of varying the assumed intertrial correlation in the studies for which an intertrial correlation cannot be calculated. If the assumed correlation for the strength measure was allowed to vary between 0.7 and 0.9 while that for the soreness and CK measures varied between 0.3 and 0.7, the overall ES would change minimally, varying from a low of 0.33 to a high of 0.35 while remaining highly significant (P .0002). Thus, the sensitivity analysis indicates that not knowing the intertrial correlations for 10 of the crossover studies probably had minimal effect on the overall ES as well as its qualitative assessment as a small to moderate effect.
Although causal conclusions cannot be made from subgroup meta-analyses, our muscle group analysis suggests that NSAID use in humans may be more beneficial when the injured muscle is located in the lower body compared with the upper body ( Table 1) . From a previous review of muscle injury models, 74 it appears that injury is typically greater when induced in the upper body of humans compared with the lower body. On average, elbow flexor injury models yield a 5-fold greater peak level of blood CK compared with the knee extensor injury model, while the percentage strength loss for the elbow flexor model is~50% greater than that typically observed for the knee extensor model. We hypothesize that NSAID use may be more beneficial when the extent of muscle injury is less. Greater injury would presumably be associated with greater inflammation, and it may be difficult to inhibit such inflammation with the standard over-the-counter NSAID doses used in many of our reviewed studies. However, an over-the-counter NSAID dose may be sufficient to minimize inflammation associated with relatively minor injuries (eg, like those for knee extensors). However, we did not find study ES to be related to the extent of initial injury as assessed by the initial strength loss or to the NSAID dose ( Table 2 ). Both of these observations argue against our hypothesis. However, only 23 of the 41 studies reported initial strength loss data and only human studies were used in our NSAID dose meta-regression, so our analyses investigating these 2 factors may be underpowered statistically. To summarize, we cannot readily explain the apparent difference in NSAID effectiveness between studies of lower versus upper body muscle injury.
While previous studies have shown NSAIDs to have negative effects on muscle protein synthesis and myogenic cell regenerative properties, 5, 6, 40, 43, 48 our study overall indicates that if these effects do occur, they do not occur to the extent to adversely affect strength loss, soreness, or blood CK level during recovery from injury. Presumably, any adverse effects of NSAIDs on regenerating muscle would manifest relatively late during an injured muscle's recovery, at least compared with timing of the inflammatory response. A failure to observe adverse effects of NSAIDs on muscle regeneration may result from experimental design limitations of the studies included in our review. For example, no human studies assessed injury markers after 14 days after injury ( Figure 4B ) whereas half of the animal studies did, and in those studies, study ES decreased with time such that study ES was negative in 6 of 8 observations at 14 or more days after injury ( Figure 4A ). There was also a large difference between human and animal studies in the duration of NSAID administration. One might hypothesize that the longer NSAIDs are administered, the greater the likelihood for impaired muscle regeneration. Only 1 animal study had NSAID administration longer than 7 days, whereas more than a third of the human studies administered NSAIDs that long or longer (Figure 3) . This difference, however, does not explain the meta-regression slope difference between the animal and human studies ( Figure 3A vs Figure 3B) . It is possible that a species difference does provide such an explanation.
In conclusion, the findings of our systematic review and meta-analysis indicate that overall, NSAID use can improve the recovery from acute muscle injury by reducing strength loss, soreness, and blood CK level. Future research is warranted based on the findings of our subgroup meta-analyses and meta-regressions. First, experimental studies should be conducted to determine whether NSAID use, in fact, has a more beneficial effect on the recovery from lower body muscle injury compared with upper body injury in humans. In those studies, it would be important to hold the magnitude of the injury constant (eg, same percentage strength loss) between the 2 muscle groups. Second, experimental studies should be conducted to determine whether NSAID use has adverse effects at later time points after injury (ie, .14 days) in humans as appears to be the case for animals. Third, it is important to determine experimentally how the duration of NSAID use affects recovery from injury and whether that relationship is different between humans and animals. Finally, the mechanism(s) for the beneficial effect of NSAIDs on injury recovery should be determined. At least in humans, the mechanisms are probably not attributable to a direct effect on myogenic precursor cells or muscle regeneration. For the clinician, our findings indicate that NSAIDs have a small to moderate, beneficial effect on reducing strength loss, pain, and blood CK level after an acute muscle injury in patients and that there is no evidence for adverse effects on muscle as suggested by some of the animal data. Although we did not specifically investigate the adverse side effects that NSAIDs might have on other organ systems with prolonged use, short-term treatment with standard over-the-counter NSAID doses would appear warranted.
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